FDA Fast Tracks Regenxbio Gene Therapy
The FDA granted Regenxbio RGX-202, a prospective gene therapy for Duchenne Muscular Dystrophy, a Fast Track designation.
The FDA granted Regenxbio RGX-202, a prospective gene therapy for Duchenne Muscular Dystrophy, a Fast Track designation.
Parent Project Muscular Dystrophy and Duchenne UK launch their 2022 Joint Call for Therapeutic Projects inviting research proposals.
A drug first developed to treat kidney disease prolongs survival and improves muscle function in mice with Duchenne, Johns Hopkins reports.
The Oxford-Harrington Rare Disease Centre announce its support of a novel treatment for Duchenne muscular dystrophy.
Read MoreSarepta Therapeutics Inc announces its intent to submit a BLA seeking accelerated approval for SRP-9001 to treat individuals with Duchenne.
Read MoreCIONIC announces a collaboration with acclaimed designer Yves Behar and his world-renowned multidisciplinary design firm, fuseproject.
Read MoreParent Project Muscular Dystrophy adds the clinic at UPMC Children’s Hospital of Pittsburgh to its Certified Duchenne Care Center Program.
Read MoreFulcrum Therapeutics is using AMRA Medical’s muscle fat infiltration (MFI) as a secondary endpoint in its phase 3 FSHD clinical trial: REACH.
Read MoreParent Project Muscular Dystrophy expands its Certified Duchenne Care Program with the certification of the first clinic in St. Louis.
Read MoreMutations that cause Duchenne muscular dystrophy slow electrical activity in the heart, causing abnormal heart rhythms, a study notes.
Read MoreAMRA Medical publishes results of its Fulcrum-sponsored study highlighting the development and use of a MRI protocol for muscle analysis.
Read MoreParent Project Muscular Dystrophy nominates Duchenne to be part of Recommended Uniform Screening Panel (RUSP) for newborns.
Read MoreICD-10-CM codes for LGMD and several of its subtypes will be fully implemented and ready for use starting this October, MDA reports.
Read MoreAn existing cancer drug could have potential as a treatment for muscular dystrophy, researchers suggest in a new study.
Read MoreParent Project Muscular Dystrophy will host its 2022 Annual Conference in Scottsdale, Arizona, June 23-26.
Read MoreAvidity Biosciences Inc joins in activities to raise awareness for FSHD and highlights preclinical treatment results supporting AOC 1020.
Read MoreThe FSHD Society is holding back-to-back meetings in June in Orlando to help develop treatments for facioscapulohumeral muscular dystrophy.
Read MoreMDA Rivals on Saturday, June 18, aims to support funding for people living with muscular dystrophy, ALS, and related neuromuscular diseases.
Read More